Avalyn Pharma officer exercises options, sells shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Douglas R. Carlson, Avalyn Pharma Inc. (AVLN)’s Chief Financial and Business Officer, exercised 14,875 stock options at a $4.62 exercise price on November 17, 2026, receiving common shares. His sales comprised 11,527 shares at a weighted average price of $27.7810, 3,093 at $28.2246, and 255 at $29.2267. The transactions were made under a Rule 10b5-1 trading plan adopted July 30, 2026. After the exercise, his reported stock-option position was 255,623 shares.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 14,875 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 14,875 | $4.62 | $69K |
| Sale | Common Stock F1, F2 | 11,527 | $27.781 | $320K |
| Sale | Common Stock F1, F3 | 3,093 | $28.2246 | $87K |
| Sale | Common Stock F1, F4 | 255 | $29.2267 | $7K |
Footnotes (5)
- F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.06 to $28.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.06 to $29.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.09 to $29.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F5. 25% of the shares underlying this option vested and became exercisable on May 1, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
vested financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.